TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12799626
Drug: Darbepoetin alpha
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alpha Q4W (6.75 or 10.0 micro g kg(‐1) for 12 weeks)
Study: 8195451
Drug: Clonazepam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (mean dose 2.2 mg, SD 0.7 mg)
Study: 28328526
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (100,000 IU single oral dose)
Study: 24034569
Drug: High-dose Asiatic
Normalized name: asiatic acid
DrugBank: Asiatic acid (DB14054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Asiatic plantain extract (20 g/80 mL)
Study: 21964893
Drug: Bevacizumab containing
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab containing chemotherapy
Study: 17052276
Drug: PEG‐IFN (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN (180 microg sc weekly) and standard dose of RBV (1000/1200 mg po daily, STD)
Study: 17052276
Drug: PEG‐IFN (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN (180 microg sc weekly) and low‐dose of RBV (600/800 mg po daily, LOW)
Study: 12588538
Drug: Investigational anticancer
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational anticancer drugs
Study: 12588538
Drug: Earlier phases
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earlier phases of investigational anticancer drugs
Study: 8445198
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone given within 8 hours of spinal cord injury
Study: 27209422
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) in the form of exposure and response prevention, 14 weekly sessions
Study: 16520033
Drug: 60 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/m2 every 6 weeks (ARM A)
Study: 16520033
Drug: 50 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m2 every 4 weeks (ARM B)
Study: 10714017
Drug: Nicorandil pretreatment
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil pretreatment (0.3 mg/kg) 30 minutes before aortic cross clamping
Study: 8959996
Drug: Riluzole (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (any dose)
Study: 25523190
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin D therapy
Study: 29533998
Drug: Depot vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot vitamin D therapy
Study: 25782919
Drug: Ropivacaine (0.25%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (0.25%, 40 mL)
Study: 25782919
Drug: Control (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.9% saline, 40 mL)
Study: 24447501
Drug: Levosimendan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (6 μg/kg loading dose followed by 0.1 μg/kg/min infusion for 24 hours)
Study: 25053182
Drug: Standard inotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard inotropic therapy
Study: 20150300
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of mild GDM during pregnancy
Study: 11547841
Drug: Milk supplementation
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplementation (50 g of milk powder containing 800 mg of calcium per day)
Study: 23998557
Drug: Propionyl-L-carnitine (PLC)
Normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (PLC)
Study: 31917621
Drug: Thrombomodulin alfa
Normalized name: Thrombomodulin Alfa
DrugBank: Thrombomodulin Alfa (DB05777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombomodulin alfa (380 U/kg/d for 14 days by intravenous drip infusion)
Study: 17692438
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) route with 3, 6, or 9 microg of vaccine
Study: 17692438
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) route with 15 microg of vaccine
Study: 17692438
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) route
Study: 12373440
Drug: 0.25 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 g/kg alcohol
Study: 12373440
Drug: 0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/kg alcohol
Study: 28035589
Drug: Caspofungin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 100 mg loading dose followed by 50 mg maintenance dose for patients with total body weight of ≤80 kg
Study: 28035589
Drug: Caspofungin 70
Normalized name: caspofungin 70 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 70 mg maintenance dose for patients with total body weight of >80 kg
Study: 23375819
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 3 g/d
Study: 23375819
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (0.5‐1 g/m²)
Study: 21516030
Drug: tesamorelin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tesamorelin (2 mg subcutaneously daily for 26 weeks)
Study: 21516030
Drug: placebo (subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (subcutaneously daily for 26 weeks)
Study: 17279300
Drug: Ciprofloxacin 1
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1 g/day and tinidazole 15 mg/kg/day for 4 weeks
Study: 17279300
Drug: Mesalamine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine (4 g/day oral, 8 g/day enema, or 1 g/day suppository)
Study: 15484217
Drug: Low-dose suramin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose suramin
Study: 15484217
Drug: Intermediate-dose suramin
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose suramin
Study: 15484217
Drug: High-dose suramin
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose suramin
Study: 16689755
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups post-treatment
Study: 8028755
Drug: carbocalcitonin +
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: carbocalcitonin + arginine-lysine-lactose combination
Study: 2653110
Drug: Testosterone-undecanoate 120
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone-undecanoate 120 mg per os for 100 days
Study: 887645
Drug: 300 IU
Normalized name: Follistim AQ 300 IU per 0.36 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IU daily of synthetic oxytocin
Study: 887645
Drug: 600 IU
Normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU daily of synthetic oxytocin
Study: 31561192
Drug: Real-time medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time medication monitoring pill bottle linked to an HIV self-management app
Study: 1445478
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg q.d.
Study: 1445478
Drug: Hydroxyzine 25
Normalized name: hydroxyzine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 25 mg t.i.d.
Study: 22048237
Drug: Selumetinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (100 mg orally twice daily in 28-day cycles)
Study: 22048237
Drug: Temozolomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (200 mg/m2/day for 5 days, then 23 days off-treatment)
Study: 1836986
Drug: Cilazapril 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 5.0 mg/day
Study: 1836986
Drug: Cilazapril 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 10.0 mg/day
Study: 30962603
Drug: Personalized information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized information treatments targeting parents' misbeliefs about their children's absences
Study: 23592025
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TNA) 10 mg/kg administered intravenously 20 min before tourniquet deflation and repeated 3 h after surgery for unilateral TKA; an additional dose of TNA 10 mg/kg before tourniquet deflation for the second TKA in bilateral TKA patients.
Study: 17216337
Drug: Aqua‐E (water-soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqua‐E (water-soluble vitamin E formulation)
Study: 14675055
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg orally for 10 days during LBNP
Study: 3912093
Drug: Intravenous PGE1
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous PGE1 (15 micrograms/h for 72 h)
Study: 31676660
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Group Therapy (CRGT) - combining mindfulness-based stress reduction with brain training activities
Study: 31676660
Drug: Mutual Aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mutual Aid Group Therapy (active control)
Study: 31676660
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (CRGT and Mutual Aid Group Therapy)
Study: 26797106
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g and tramadol 1 mg/kg (group 1T)
Study: 26797106
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g and tramadol 1.5 mg/kg (group 1.5T)
Study: 15515192
Drug: Urokinase (UK)
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urokinase (UK) instillation (100,000 IU in 150 ml normal saline daily)
Study: 15515192
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-tuberculous agents only)
Study: 11584199
Drug: Surgery with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery with dissection of the lateral lymph nodes including autonomic nerves (D2) followed by oral administration of carmofur for one year
Study: 8200466
Drug: Balloon catheter
Normalized name: Paclitaxel coated angioplasty balloon catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon catheter with extra-amniotic saline infusion (BCEAS)
Study: 23743017
Drug: Dialysate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate sodium concentration 135 mmol/L
Study: 23743017
Drug: Dialysate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate sodium concentration 145 mmol/L
Study: 22059307
Drug: Weekly 75-minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 75-minute play program throughout the school year
Study: 18272271
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 40 mg/day for 4 days
Study: 12488233
Drug: Oroenteral diets
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oroenteral diets (oral drinks or duodenal infusions of complex formula)
Study: 6429872
Drug: Intravenous feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous feeding
Study: 12488233
Drug: Elemental formula
Normalized name: Elemental formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental formula (duodenal infusion)
Study: 8650464
Drug: Clonidine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (mean = 0.5 mg/day)
Study: 3158125
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 mg, long‐acting preparation)
Study: 23293082
Drug: Dexamethasone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (40 mg/day for 4 days)
Study: 30882644
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality immersive training with computerized cognitive therapy (experimental group)
Study: 30882644
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive therapy (control group)
Study: 24727841
Drug: Rituximab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1 g at weeks 0 and 2)
Study: 20571129
Drug: Low magnitude,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low magnitude, high frequency mechanical stimulation (active treatment)
Study: 18612883
Drug: Bupropion (BUPRO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (BUPRO, 300 mg/day)
Study: 7594332
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of 30 mg twice daily of lansoprazole
Study: 7594332
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip infusion of 30 mg twice daily of lansoprazole
Study: 7594332
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of 60 mg once daily of lansoprazole
Study: 7594332
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection (30 mg twice daily) vs intravenous bolus injection (60 mg once daily)
Study: 7594332
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection vs intravenous drip infusion
Study: 2302074
Drug: Lactate (LA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate (LA) bath (Na, 138; K, 1.5; Ca, 1.75; Mg, 0.75; Cl, 109.5; AC, 17.5; and D,L‐lactate, 17.5 mmol/L)
Study: 2302074
Drug: Acetate (AC)
DrugBank: Acetate (DB14511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate (AC) bath (35 mmol/L)
Study: 27767328
Drug: Fluticasone Furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone Furoate and Vilanterol (FF/VI; 100 μg and 25 μg respectively)
Study: 16925790
Drug: Apotransferrin (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apotransferrin (dosage regimens not specified)
Study: 11255425
Drug: Ipriflavone, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone, 200 mg 3 times per day (n = 234)
Study: 8373842
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptives (Group III)
Study: 31856838
Drug: AZD8848 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8848 60 μg
Study: 26160083
Drug: Single intra-operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intra-operative injection of triamcinolone (0.5-1cc of triamcinolone 40mg/cc)
Study: 26160083
Drug: Intra-operative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-operative and two post-operative injections of triamcinolone (0.5-1cc of triamcinolone 40mg/cc)
Study: 17610807
Drug: Direct individual
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct individual therapy
Study: 19107656
Drug: Indirect individual
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect individual therapy
Study: 19107656
Drug: Direct group
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct group therapy
Study: 17610807
Drug: Indirect group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect group therapy
Study: 19107656
Drug: Usual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual therapy control group
Study: 8982417
Drug: n-docosanol 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-docosanol 10% cream (early treatment)
Study: 8982417
Drug: n-docosanol 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-docosanol 10% cream (late treatment)
Study: 1607535
Drug: Heparin (intravenous)
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin (intravenous)
Study: 19588640
Drug: Topical AzA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical AzA 15% gel and oral doxycycline (100 mg), both twice daily for ≤ 12 weeks
Study: 19588640
Drug: Topical AzA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical AzA 15% gel
Study: 19588640
Drug: Both AzA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both AzA gel and vehicle
Study: 14706014
Drug: estramustine phosphate
Normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estramustine phosphate (560 mg/day) plus LHRH agonist
Study: 14706014
Drug: flutamide (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: flutamide (375 mg/day) plus LHRH agonist
Study: 8311350
Drug: urapidil (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: urapidil (0.4 mg.kg‐1)
Study: 27060705
Drug: Multiple-micronutrient (MMN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-micronutrient (MMN) capsules
Study: 27060705
Drug: Iron-folate (IFA)
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron-folate (IFA) capsules
Study: 19695406
Drug: Nilotinib 400
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 400 mg BID for 15 days
Study: 3310670
Drug: 250‐mg disulfiram
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250‐mg disulfiram
Study: 3310670
Drug: 1‐mg disulfiram
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐mg disulfiram
Study: 27256812
Drug: Cocktail of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail of digoxin (0.25 mg), furosemide (5 mg), metformin (500 mg), and rosuvastatin (10 mg)
Study: 27256812
Drug: Cocktail of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail of digoxin, furosemide, metformin, and rosuvastatin
Study: 27256812
Drug: Increased doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased doses of metformin
Study: 27256812
Drug: Increased doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased doses of furosemide
Study: 25975013
Drug: Salt supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt supplements (1/8th teaspoon salt, 750 mg) mixed in formula feeds 1 day prior to sweat testing
Study: 25975013
Drug: No salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: No salt supplement (control group)
Study: 16473462
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of local anesthetic
Study: 14612001
Drug: Daclizumab 1
Normalized name: daclizumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 1 to 1.5 mg/kg on day 1 and day 5 posttransplant
Study: 14612001
Drug: Methylprednisolone intraoperatively
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone intraoperatively followed by Neoral monotherapy, with Cellcept for 2-4 months
Study: 28708791
Drug: Laparoscopic total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic total mesometrial resection (L-TMMR)
Study: 19589891
Drug: Aggressive disease
Normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive disease management (e.g., infliximab treatment)
Study: 3618627
Drug: Crystalline fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crystalline fructose (60 g) supplementation
Study: 29777278
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in platelet count of 20 × 10^9/L
Study: 19020154
Drug: Intranasal ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketorolac 31.5 mg
Study: 16417730
Drug: CRASH protocol
Normalized name: Rash Relief Antibacterial
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CRASH protocol with 3 mg of cetrorelix and stimulation with recombinant human FSH starting on cycle day 2
Study: 10532103
Drug: Complex therapy
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex therapy including immunotherapy with epithalamin 100 mg, neoadjuvant intraarterial polychemotherapy with 5-fluorouracil 2 g/m2 and cisplatin 100 mg/m2, concurrent radiotherapy, and 4-6 courses of adjuvant polychemotherapy
Study: 4072875
Drug: Cibenzoline (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (130 mg twice daily and 160 mg twice daily)
Study: 4072875
Drug: Quinidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (300 mg every 6 hours and 400 mg every 6 hours)
Study: 20522535
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg thrice weekly after dialysis
Study: 10551054
Drug: Litt's Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Litt's Oral Surgery Confidence Questionnaire (OSCQ)
Study: 1984229
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic therapy (amoxicillin)
Study: 6954863
Drug: Multivitamin-trace mineral
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin-trace mineral supplement
Study: 30403366
Drug: Impella therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impella therapy
Study: 20094958
Drug: Amitriptyline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (mean dosage 55 mg, range: 12.5-150 mg) taken at bedtime following a self-titration protocol.
Study: 18242045
Drug: Contraception and
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraception and postmenopausal hormone replacement therapy
Study: 18242045
Drug: Rituximab and
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab and other drugs (anti-BAFF, TACI-Fc)